PAXMEDICA, INC.

(PXMD)
Delayed Nasdaq  - 
0.000000 USD    0.00%
04/25PaxMedica, Inc. announced a financing transaction
CI
01/07PaxMedica, Inc. Plans to Initiate Phase 1B Study for PAX-101 in Patients with Long COVID-19 Syndrome
CI
01/04PaxMedica, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
SummaryNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about PAXMEDICA, INC.
04/25PaxMedica, Inc. announced a financing transaction
CI
01/07PaxMedica, Inc. Plans to Initiate Phase 1B Study for PAX-101 in Patients with Long COVI..
CI
01/04PaxMedica, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
2021Paxmedica, Inc. Presents Clinical Data and New Analyses from A Phase 2 Trial of Pax-101..
CI
2021PaxMedica to Present Data from its Recent Phase 2 Trial of PAX-101 (IV suramin) in Chil..
CI
2021PaxMedica Announces Positive Results from Phase 2 Trial of PAX-101 (IV suramin) in Chil..
CI
2020PaxMedica, Inc. announced that it has received $3 million in funding
CI
2020PaxMedica, Inc. announced that it expects to receive $3 million in funding
CI
2020PaxMedica, Inc. has filed an IPO in the amount of $18.4575 million.
CI